Technological Advancements Extend Long-Term Survival of Transplanted Hearts Across Species
Presentation at 94th AATS Annual Meeting Describes Combination of Donor Genetic Modifications and Host-Targeted Immunosuppression
Embargo expired: 28-Apr-2014 2:20 PM EDT
Source Newsroom: American Association for Thoracic Surgery (AATS)
Newswise — Toronto, ON, Canada, April 28, 2014 – Cardiac transplantation is the treatment of choice for end stage heart failure. According to the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, approximately 3,000 people in the US are on the waiting list for a heart transplant, while only 2,000 donor hearts become available each year. Therefore for the cardiac patients currently waiting for organs, mechanical assist devices are the only options available. These devices, however, are not perfect and have issues with power supplies, infection, and both clotting and hemolysis.
Transplantation using an animal organ, or xenotransplantation, has been proposed as a valid option to save valuable human lives. Muhammad M. Mohiuddin, MD, of the Cardiothoracic Surgery Research Program at the NHLBI, and co-investigators have now developed techniques to overcome some of the immunologic roadblocks that hinder successful xenotransplantation using genetically engineered pigs as a source of donor organs. Pigs were chosen because their anatomy is compatible with that of humans and they have a rapid breeding cycle, among other reasons.
As the result of recent improvements in technology for genetic modification of pigs, genes that are immunogenic for humans have been eliminated (‘knocked out”) and several human genes have been added to the pig genome. Grafts from these genetically engineered (GE) pigs are less likely to be seen as foreign, thus reducing the immune reaction against them. These modifications should also allow transplants utilizing lower amounts of toxic immunosuppressive drugs.
“These recent scientific developments in the field of genetic engineering, along with the generation of novel target specific immune suppression, and their favorable impact on organ and cellular transplantation, may instill a new ray of hope for thousands of patients waiting for human donor organs,” comments Dr. Mohiuddin.
The NHLBI group was fortunate to have access to GE pigs through close collaboration with Revivicor, Inc. Experiments using these GE pig hearts, transplanted in the abdomen of baboons along with their native hearts, were designed to study the usefulness of these GE pigs along with several new target-specific immunosuppressive agents in prolonging the graft survival. Through the combination of a pig heart with certain gene modifications, with drugs suppressing both T and B cell immune responses, investigators were able to prolong the graft survival in baboons to over one year. This unique achievement by the NIH laboratory is twice as long as previously reported.
The long-term surviving grafts exhibit normal histology (cellular architecture) and contractility. The researchers’ next step is to use hearts from the same GE pigs with the same immunosuppression utilized in the current experiments to test their ability to provide full life support by replacing the original baboon heart.
“Based on the data from long-term surviving grafts, we are hopeful that we will be able to repeat our results in the life-supporting model. If successful, this method could change the current transplant paradigm, eliminating the shortage of donor organs including hearts, livers, kidneys, intestine, as well as insulin producing cells for treatment of diabetes,” concludes Dr. Mohiuddin. He is presenting the results of this research at the 94th AATS Annual Meeting in Toronto, ON, Canada on April 28, 2014.
# # #
NOTES FOR EDITORS
“Genetically Engineered Pigs And Target-Specific Immunomodulation Provide Significant Graft Survival and Hope for Clinical Cardiac Xenotransplantation,” by Muhammad M. Mohiuddin, MD, Avneesh K. Singh, PhD, Philip C. Corcoran, MD, Robert F. Hoyt, DVM, Marvin L. Thomas III, DVM, David Ayares, PhD, Keith A. Horvath, MD. Presentation at the 94th AATS Annual Meeting. April 26-30, 2014. Toronto, ON, Canada, during the Adult Cardiac Surgery Session on April 28, 2:20 PM ET. http://aats.org/annualmeeting
For more information contact Nicole Baritot, Managing Editor, AATS Scientific Publications, at +1 978-299-4520 or firstname.lastname@example.org. Journalists wishing to interview Dr. Mohiuddin may contact him via the NHLBI Office of Health Education, Communications, and Science Policy at +1 301-496-4236 (ask for the press officer on duty) or email@example.com. The presentation abstract is located at http://aats.org/annualmeeting/Program-Books/2014/9.cgi.
ABOUT THE AUTHORS
Muhammad M. Mohiuddin, MD, Cardiothoracic Surgery Research Program, NHLBI, NIH, Bethesda, MD, USA
Avneesh K. Singh, PhD, Cardiothoracic Surgery Research Program, NHLBI, NIH, Bethesda, MD, USA
Philip C. Corcoran, MD, Cardiothoracic Surgery Research Program, NHLBI, NIH, Bethesda, MD, USA
Robert F. Hoyt, DVM, Laboratory Animal Sciences Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, MD, USA
Marvin L. Thomas III, DVM, Division of Veterinary Resources, NIH, Bethesda, MD David Ayares, PhD, Revivicor, Inc., Blacksburg, VA, USA
Keith A. Horvath, MD, Cardiothoracic Surgery Research Program, NHLBI, NIH, Bethesda, MD, USA
ABOUT THE AMERICAN ASSOCIATION FOR THORACIC SURGERY (AATS)
The American Association for Thoracic Surgery (AATS) is an international organization of over 1,300 of the world’s foremost thoracic and cardiothoracic surgeons, representing 35 countries. AATS encourages and stimulates education and investigation into the areas of intrathoracic physiology, pathology and therapy. Founded in 1917 by a respected group of the last century’s earliest pioneers in the field of thoracic surgery, the AATS’ original mission was to “foster the evolution of an interest in surgery of the Thorax.”
One hundred years later, the AATS continues to be the premiere association among cardiothoracic surgeons. The purpose of the Association is the continual enhancement of the ability of cardiothoracic surgeons to provide the highest level of quality patient care. To this end, the AATS encourages, promotes, and stimulates the scientific investigation and study of cardiothoracic surgery. Visit www.aats.org.